Cash-strapped Gemphire lets go of five staffers as it contends with a clinical hold
Scrapping for cash to produce additional safety data requested by the FDA before it could proceed with its lead drug, Gemphire has cut into its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
